Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party-Reference-Cited by-同舟云学术

Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party

Published:2019-02-21 Issue:9 Volume:104 Page:e398-e401
ISSN:0390-6078
Container-title:Haematologica
language:en
Short-container-title:Haematologica

Author:

Bazarbachi Ali,Labopin Myriam,Battipaglia Giorgia,Djabali Azedine,Passweg Jakob,Socié Gerard,Forcade Edouard,Blaise Didier,Chevallier Patrice,Orvain Corentin,Cornelissen Jan J.,Arcese William,Chantepie Sylvain,Hashaishi Khowla,Cheikh Jean El,Medinger Michael,Esteve Jordi,Nagler Arnon,Mohty Mohamad

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic insights and immune microenvironment delineation in acute myeloid leukemia by ferroptosis-derived signature;Heliyon;2024-03

2. Extracellular Vesicles: Biology and Their Use as Potential Biomarkers in Hematopoietic Post-Transplant Complications;Comprehensive Hematology and Stem Cell Research;2024

3. Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyond;Cytotherapy;2023-12

4. Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD;Trials;2023-09-15

5. Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party;Clinical Cancer Research;2023-08-21